Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer
US10925867B2 · kind B2 · utility
0Cited by
19References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2016 |
| Grant date | Feb 23, 2021 |
| Priority date | — |
| Expiry date | Jul 26, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.